News and Media

Latest News Release
01/31/2024

Transaction creates increased clinical and economic value for 11,500 specialty providers, including more than 7,000 physicians across 1,200 independent physician practices Transaction creates...

Top feature box IMAGE ONLY - COMPANY NEWS

Press Releases

Phoenix Grants AccessClosure Emerging Growth Company Award
09/25/2014

DUBLIN, Ohio, Sept. 25, 2014 /PRNewswire/ -- AccessClosure, a Cardinal Health company, recently won the Emerging Growth Company Award from Phoenix, a medical device and diagnostics conference for chief executive officers.

The Phoenix Emerging Growth Company Award recognizes outstanding achievement by an emerging growth company during the previous 24 months. The award is presented to a company that has undergone one of the following events: a strategically significant merger, a highly successful IPO, dramatic growth in sales or the creation of a major new product or service. The Phoenix awards are presented for outstanding achievement in the medical device and diagnostic industry to individuals and companies selected by industry CEOs.

"This award recognizes AccessClosure's spirit of innovation and growth and is affirmation of the great example AccessClosure provides in innovative solutions for the health care industry," said Mike Duski, senior vice president and general manager, Interventional Solutions, Cardinal Health. "With Cardinal Health's resources and customer relationships, we are excited to build on this platform to become the partner of choice for solutions that improve patient care while reducing the total cost of care for hospital systems."

Phoenix: The Medical Device and Diagnostic Conference for Chief Executive Officers began in 1994. The conference was developed to provide CEOs in the medical device and diagnostic industries with an opportunity to meet with peers and explore issues critical to the success of their companies and industries.

Past recipients of the Emerging Growth Company Award include Ardian, Acclarent, CoreValve, SurgRx, IntraLase, Advanced Neuromodulation Systems, Fox Hollow, Kyphon, Align, TheraSense, PercuSurge, ArthoCare, VISX, Arterial Vascular Engineering, Volcano and Target Therapeutics.

About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products and services to more than 100,000 locations each day and is also the industry-leading direct-to-home medical supplies distributor. The company is a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company operates the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #22 on the Fortune 500, Cardinal Health employs 34,000 people worldwide. More information about the company may be found at www.cardinalhealth.com and @CardinalHealth on Twitter.

SOURCE Cardinal Health

For further information: Media: Corey Kerr, (614) 757-3383, corey.kerr@cardinalhealth.com; Investors: Erika Wadlinger, (614) 757-5035, erika.wadlinger@cardinalhealth.com
More Company News
04/02/2024

The Consumer Health Logistics Center will be located in Central Ohio and serve as a centralized hub for distribution of consumer health products COLUMBUS, Ohio, April 2, 2024 /PRNewswire/ --...

03/26/2024

Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will...

03/15/2024

Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions...

02/29/2024

Study reveals impact of dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability DUBLIN, Ohio, Feb. 29, 2024...

View all company news »